Skip to content

Study · Animal study (in vivo) · mouse · 1991

4 results

Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.

Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E

Cellular immunology1 Mar 1991Cited by 17 (Europe PMC)

PMID1991327 (opens in a new tab)DOI10.1016/0008-8749(91)90191-d (opens in a new tab)PepBankPUB-01991327
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In normal and immunosuppressed mice, in vivo pretreatment with thymosin alpha‑1 significantly increased IL-2-induced cytotoxic activity of spleen lymphocytes against YAC-1 (NK-sensitive) cells.

    In plain wordsIn mice, thymosin alpha‑1 pretreatment boosted IL-2-induced killing of YAC-1 cells by spleen cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2-induced cytotoxic activity against YAC-1 cells after in vivo pretreatment
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    200 micrograms/kg/day · 4 daysAs given in this study (mouse).

    Source sentences

    Summary
    pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppresse…
    1 context sentence
    Summary · context
    We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In normal and immunosuppressed mice, in vivo pretreatment with thymosin alpha‑1 significantly increased IL-2-induced cytotoxic activity of spleen lymphocytes against MBL-2 (NK-resistant) cells.

    In plain wordsIn mice, thymosin alpha‑1 pretreatment boosted IL-2-induced killing of MBL-2 cells by spleen cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2-induced cytotoxic activity against MBL-2 cells after in vivo pretreatment
    Study

    mousen: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    200 micrograms/kg/day · 4 daysAs given in this study (mouse).

    Source sentences

    Summary
    pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppresse…
    1 context sentence
    Summary · context
    We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1).
  3. 03LabEx vivo tissueEfficacy outcome

    In spleen lymphocytes from normal and immunosuppressed mice, in vitro pretreatment with thymosin alpha‑1 significantly increased IL-2-induced cytotoxic activity against YAC-1 (NK-sensitive) cells.

    In plain wordsIn mouse spleen cells in the lab, thymosin alpha‑1 pretreatment boosted IL-2-induced killing of YAC-1 cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2-induced cytotoxic activity against YAC-1 cells after in vitro pretreatment
    Study

    mousen: not reported in source

    Spleen lymphocytes from normal and cyclophosphamide- or tumor-suppressed mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    100 ng/ml · 1 hrAs given in this study (mouse).

    Source sentences

    Summary
    pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppresse…
    1 context sentence
    Summary · context
    We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1).
  4. 04LabEx vivo tissueEfficacy outcome

    In spleen lymphocytes from normal and immunosuppressed mice, in vitro pretreatment with thymosin alpha‑1 significantly increased IL-2-induced cytotoxic activity against MBL-2 (NK-resistant) cells.

    In plain wordsIn mouse spleen cells in the lab, thymosin alpha‑1 pretreatment boosted IL-2-induced killing of MBL-2 cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2-induced cytotoxic activity against MBL-2 cells after in vitro pretreatment
    Study

    mousen: not reported in source

    Spleen lymphocytes from normal and cyclophosphamide- or tumor-suppressed mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    100 ng/ml · 1 hrAs given in this study (mouse).

    Source sentences

    Summary
    pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppresse…
    1 context sentence
    Summary · context
    We have investigated the effects of interleukin 2 (IL-2) on cytotoxic activity of spleen lymphocytes, from normal and cyclophosphamide (200 mg/kg) or B-16 melanoma suppressed mice, after in vitro or in vivo pretreatment with thymosin alpha 1 (TA1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.